US Edition
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
- WeightWatchers filed for bankruptcy on May 7, 2025, citing declining customer interest and competition from weight-loss drugs in the U.S. wellness market.
- The bankruptcy followed a shift in consumer preference toward GLP-1 agonist drugs like Wegovy and Zepbound, which can reduce weight by 15%-20%.
- WeightWatchers' traditional system, based on points and in-person meetings, failed to compete with telehealth companies that fully embrace prescribing these drugs.
- Telehealth companies see clinical subscriptions with weight-loss drugs as a growing revenue source, but FDA restrictions on cheaper compounded drug versions pose a challenge.
- The bankruptcy implies the wellness industry must innovate partnerships with drugmakers and adapt to changing consumer demands shaped by new medications and social media influences.
14 Articles
14 Articles
Q&A: Rip-off train fares, vile Andrea Jenkyns and bye bye Weightwatchers
The Matts get their heads around the cost of travelling in the UK by train, wonder if the death of Weightwatchers signifies a stage of human evolution, lament the disgraceful comments of Reform’s Andrea Jenkyns and offer their guiding hand to Downing Street… enjoy!EXCLUSIVE OFFER: Get The New European for just £1 for the first […]
Striving for ‘Imprefection’ | Meetings, milestones and the end of an era
This column will be unlike most of my columns; Weight Watchers shaped much of my life. Then it changed. If you haven’t heard, it’s now in bankruptcy. I wanted to share some thoughts about my history with it. If you’re around my age — or somewhere nearby — you probably spend more time these days thinking about how much life is in the rearview mirror. As John Mellencamp put it in “The Real Life”: “But something happens when you reach a certain age…
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
WeightWatchers filed for bankruptcy on Tuesday as Americans shunned its offerings in favor of Novo and Lilly drugs and copies from pharmacies that can cut a person's weight by as much as 20%.
Coverage Details
Bias Distribution
- 55% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
